title: Increased tissue factor pathway inhibitor in patients with acute myocardial infarction.
abstract: We examined hemostatic abnormalities in 23 patients with acute myocardial infarction (AMI), 10 with pulmonary embolism (PE), and 10 with deep vein thrombosis (DVT). At the onset of AMI, plasma levels of tissue-type plasminogen activator (t-PA), PA inhibitor-I (PAI-I), fibrin-D-dimer, thrombin-antithrombin complex (TAT), and plasmin-plasmin inhibitor complex (PPIC) were significantly increased. Both the plasma total TFPI and free-TFPI levels in the AMI patients were significantly higher than those in the healthy volunteers, PE patients, and DVT patients. There was no significant difference in total TFPI or free-TFPI among patients with PE, those with DVT, and healthy volunteers. One hour after percutaneous transluminal coronary angioplasty (PTCA) in the AMI group, the total TFPI level was further increased, and it was significantly reduced 24 hr after PTCA, to a level similar to that in healthy volunteers. Free-TFPI showed a pattern similar to that of total TFPI. The ratio of free-TFPI/total TFPI was highest 1 hr after PTCA. Increased TFPI in AMI patients might be released from ischemic tissues.
authors.affiliation: Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie-ken, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kamikura
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: A
authors.initials: A
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Shimura
authors.forename: K
authors.initials: K
authors.lastname: Hiyoyama
authors.forename: H
authors.initials: H
authors.lastname: Shiku
authors.forename: M
authors.initials: M
authors.lastname: Tanigawa
authors.forename: H
authors.initials: H
authors.lastname: Nishikawa
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: N
authors.initials: N
authors.lastname: Isaka
authors.forename: T
authors.initials: T
authors.lastname: Nakano
authors.forename: K
authors.initials: K
authors.lastname: Kumeda
authors.forename: H
authors.initials: H
authors.lastname: Kato
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D000933:Antifibrinolytic Agents / Q000032:analysis / Q000097:blood; D000990:Antithrombin III / Q000032:analysis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood*; D010447:Peptide Hydrolases / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011655:Pulmonary Embolism / Q000097:blood; D013927:Thrombosis / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D008074:Lipoproteins; D017395:Plasminogen Activator Inhibitor 1; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C051928:lipoprotein-associated coagulation inhibitor; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin